Paris, France, April 3, 2013 – Nanobiotix (Euronext: NANO), the oncology focused nanomedicine company, announces that its CEO and co-founder, Dr. Laurent Levy, has received the UB Entrepreneurship Award at the Annual Inventors and Entrepreneurs Reception on March 25 2013 at the University at Buffalo (UB), Buffalo, NY, USA, which he attended as guest of honor.
The award recognizes individuals that have championed a UB technology to create a highly successful company and whose products will have a beneficial impact on the lives of people worldwide.
Commenting on the award, Dr. Levy said: “I would like to thank everyone who has worked so hard for Nanobiotix over the past 10 years to develop the NanoXray technology, including those from the University at Buffalo who have provided substantial academic support. This recognition follows a decade of dedicated research and industrial development to realize the vision of a revolutionary nanomedicine technology for the local treatment of cancer, which is now under clinical development.”
Nanobiotix is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company, founded in 2003, is based on intellectual property developed by Dr. Levy during his postdoctoral research at UB's Institute for Lasers, Photonics and Biophotonics approximately 10 years ago. Nanobiotix’s first-in-class, proprietary technology, NanoXray, locally enhances the efficacy of radiotherapy inside tumors without increasing the damage to surrounding healthy tissue. Its lead compound, NBTXR3, is currently under clinical development in Europe.
Notes to Editors
Nanobiotix (Euronext: NANO / ISIN: FR0011341205) is a clinical-stage nanomedicine company pioneering novel approaches for the local treatment of cancer. The Company’s first-in-class, proprietary technology, NanoXray, enhances radiotherapy energy to provide a new, more efficient treatment for cancer patients. NanoXray products are compatible with current radiotherapy and brachytherapy treatments and are meant to treat a wide variety of cancers via multiple routes of administration. Nanobiotix’s lead product NBTXR3, based on NanoXray, is currently under clinical development for soft tissue sarcoma. The Company has partnered with PharmaEngine for clinical development and commercialization of NBTXR3 in Asia. The Company is based in Paris, France.
For more information, please visit www.nanobiotix.com
Issued for an on behalf of Nanobiotix.
To contact the Nanobiotix team at College Hill email firstname.lastname@example.org
Melanie Toyne-SewellManaging Partner